Display options
Cite
Gray E, Mitchell E, Jindal S, et al. A METHOD FOR QUANTIFICATION OF CALPONIN EXPRESSION IN MYOEPITHELIAL CELLS IN IMMUNOHISTOCHEMICAL IMAGES OF DUCTAL CARCINOMA IN SITU. Proc IEEE Int Symp Biomed Imaging. 2018;2018:796-799doi: 10.1109/ISBI.2018.8363692.
Gray, E., Mitchell, E., Jindal, S., Schedin, P., & Chang, Y. H. (2018). A METHOD FOR QUANTIFICATION OF CALPONIN EXPRESSION IN MYOEPITHELIAL CELLS IN IMMUNOHISTOCHEMICAL IMAGES OF DUCTAL CARCINOMA IN SITU. Proceedings. IEEE International Symposium on Biomedical Imaging, 2018796-799. https://doi.org/10.1109/ISBI.2018.8363692
Gray, Elliot, et al. "A METHOD FOR QUANTIFICATION OF CALPONIN EXPRESSION IN MYOEPITHELIAL CELLS IN IMMUNOHISTOCHEMICAL IMAGES OF DUCTAL CARCINOMA IN SITU." Proceedings. IEEE International Symposium on Biomedical Imaging vol. 2018 (2018): 796-799. doi: https://doi.org/10.1109/ISBI.2018.8363692
Gray E, Mitchell E, Jindal S, Schedin P, Chang YH. A METHOD FOR QUANTIFICATION OF CALPONIN EXPRESSION IN MYOEPITHELIAL CELLS IN IMMUNOHISTOCHEMICAL IMAGES OF DUCTAL CARCINOMA IN SITU. Proc IEEE Int Symp Biomed Imaging. 2018 Apr;2018:796-799. doi: 10.1109/ISBI.2018.8363692. Epub 2018 May 24. PMID: 30364524; PMCID: PMC6196724.
Copy Download .nbib Format: NLM
Share it on

Proc IEEE Int Symp Biomed Imaging. 2018 Apr;2018:796-799. doi: 10.1109/ISBI.2018.8363692. Epub 2018 May 24.

A METHOD FOR QUANTIFICATION OF CALPONIN EXPRESSION IN MYOEPITHELIAL CELLS IN IMMUNOHISTOCHEMICAL IMAGES OF DUCTAL CARCINOMA IN SITU.

Proceedings. IEEE International Symposium on Biomedical Imaging

Elliot Gray, Elizabeth Mitchell, Sonali Jindal, Pepper Schedin, Young Hwan Chang

Affiliations

  1. Department of Biomedical Engineering and Computational Biology Program.
  2. Department of Cell, Developmental and Cancer Biology Oregon Health & Science University.

PMID: 30364524 PMCID: PMC6196724 DOI: 10.1109/ISBI.2018.8363692

Abstract

Ductal carcinoma in situ (DCIS) is breast cancer confined within mammary ducts, surrounded by an intact myoepithelial cell layer that prevents local invasion. A DCIS diagnosis confers increased lifetime risk of developing invasive breast cancer (IBC) and results in surgical excision with radiation, and possibly endocrine- or chemo-therapy. DCIS is known to be over treated, with associated co-morbidities. Biomarkers are needed that delineate patients at low risk of DCIS progression from patients requiring more aggressive treatment. Investigating the role of myoepithelial cell differentiation in barrier function is anticipated to provide insight into DCIS progression and delineate between low and high risk lesions. Here, we develop a high throughput technique to assess loss of myoepithelial differentiation markers. This method facilitates automated analysis of a clinically relevant histopathologic feature, as demonstrated by a high correlation with pathologist annotation (r = 0.959), and further, contributes analytical foundations to a multiplexed immunohistochemistry (IHC) approach.

Keywords: DCIS; calponin; feature engineering; invasive breast cancer; myoepithelial cell

References

  1. Sci Rep. 2017 Apr 25;7:46732 - PubMed
  2. Anal Quant Cytol Histol. 2001 Jun;23(3):218-28 - PubMed
  3. Am J Pathol. 2015 Nov;185(11):3076-89 - PubMed
  4. Cancer. 2005 May 1;103(9):1778-84 - PubMed
  5. IEEE Trans Biomed Eng. 2014 Jun;61(6):1729-38 - PubMed
  6. J Mammary Gland Biol Neoplasia. 2005 Jul;10(3):261-72 - PubMed
  7. Methods. 2014 Nov;70(1):46-58 - PubMed
  8. World J Clin Oncol. 2014 Aug 10;5(3):382-92 - PubMed
  9. Cell Rep. 2017 Apr 4;19(1):203-217 - PubMed
  10. Sci Rep. 2017 Aug 29;7(1):9900 - PubMed
  11. Breast Cancer Res. 2005;7(5):190-7 - PubMed
  12. J Mammary Gland Biol Neoplasia. 2005 Jul;10(3):231-47 - PubMed
  13. Front Biosci (Landmark Ed). 2010 Jan 01;15:226-36 - PubMed
  14. IEEE Trans Pattern Anal Mach Intell. 2012 Nov;34(11):2274-82 - PubMed

Publication Types

Grant support